North America Cancer And Tumor Biomarker-based Assay Market Size & Outlook

The cancer and tumor biomarker-based assay market in North America is expected to reach a projected revenue of US$ 11,613.2 million by 2033. A compound annual growth rate of 10.1% is expected of North America cancer and tumor biomarker-based assay market from 2025 to 2033.
Revenue, 2024 (US$M)
$4,562.5
Forecast, 2033 (US$M)
$11,613.2
CAGR, 2025 - 2033
10.1%
Report Coverage
North America

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cancer and tumor biomarker-based assay market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

North America cancer and tumor biomarker-based assay market highlights

  • The North America cancer and tumor biomarker-based assay market generated a revenue of USD 4,562.5 million in 2024.
  • The market is expected to grow at a CAGR of 10.1% from 2025 to 2033.
  • In terms of segment, breast cancer was the largest revenue generating cancer type in 2024.
  • Lung Cancer is the most lucrative cancer type segment registering the fastest growth during the forecast period.
  • Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2033.


North America data book summary

Market revenue in 2024USD 4,562.5 million
Market revenue in 2033USD 11,613.2 million
Growth rate10.1% (CAGR from 2025 to 2033)
Largest segmentBreast cancer
Fastest growing segmentLung Cancer
Historical data covered2021 - 2023
Base year for estimation2024
Forecast period covered2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer


Other key industry trends

  • In terms of revenue, North America region accounted for 41.6% of the global cancer and tumor biomarker-based assay market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 6,095.6 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer and Tumor Biomarker-based Assay Market Companies

Name Profile # Employees HQ Website
Hologic, Inc. View profile - - -
Abbott View profile - - -
F. Hoffmann-La Roche Ltd. View profile - - -
Illumina, Inc. View profile - - -
Sysmex Corp View profile 10448 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 http://www.sysmex.co.jp
Exact Sciences Corp View profile 6600 5505 Endeavor Lane, Madison, WI, United States, 53719 https://www.exactsciences.com
Guardant Health Inc View profile 1779 3100 Hanover Street, Palo Alto, CA, United States, 94304 https://www.guardanthealth.com
Myriad Genetics Inc View profile 2700 320 Wakara Way, Salt Lake City, UT, United States, 84108 https://www.myriad.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
Agilent Technologies Inc View profile 17700 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 https://www.agilent.com
Quest Diagnostics Inc View profile 48000 500 Plaza Drive, Secaucus, NJ, United States, 07094 https://www.questdiagnostics.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
BioMerieux SA View profile 13982 Marcy l’Etoile, Lyon, France, 69280 http://www.biomerieux.com

North America cancer and tumor biomarker-based assay market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer and tumor biomarker-based assay market will help companies and investors design strategic landscapes.


Breast cancer was the largest segment with a revenue share of 27.68% in 2024. Horizon Databook has segmented the North America cancer and tumor biomarker-based assay market based on breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to North America cancer and tumor biomarker-based assay market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America cancer and tumor biomarker-based assay market databook

  • Our clientele includes a mix of cancer and tumor biomarker-based assay market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America cancer and tumor biomarker-based assay market , including forecasts for subscribers. This continent databook contains high-level insights into North America cancer and tumor biomarker-based assay market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America cancer and tumor biomarker-based assay market size, by country, 2021-2033 (US$M)

North America Cancer and Tumor Biomarker-based Assay Market Outlook Share, 2024 & 2033 (US$M)

North America cancer and tumor biomarker-based assay market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online